Salgia, Ravi

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 1,964

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 796

Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer

Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchHedgehog Signaling Pathway Studies

Cited by 561

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology

Thyroid Cancer Diagnosis and TreatmentRenal cell carcinoma treatment

Cited by 550

Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells

Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers

Drug Transport and Resistance MechanismsCancer Cells and Metastasis

Cited by 339

Molecular pathways and therapeutic targets in lung cancer

Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 220

Prognostic and Predictive Value in KRAS in Non–Small-Cell Lung Cancer: A Review

Wood, K., Hensing, T., Malik, R., & Salgia, R. (2016) · JAMA Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 164

B-cell-specific diversion of glucose carbon utilization reveals a unique vulnerability in B cell malignancies

Xiao, G., Chan, L. N., Klemm, L., Braas, D., Chen, Z., Geng, H., Zhang, Q. C., Aghajanirefah, A., Cosgun, K. N., Sadras, T., et al. (2018) · Cell

Cancer, Hypoxia, and MetabolismRedox biology and oxidative stress

Cited by 129

Utilization of model-agnostic explainable artificial intelligence frameworks in oncology: a narrative review

Ladbury, C., Zarinshenas, R., Semwal, H., Tam, A., Vaidehi, N., Rodin, A. S., Liu, A., Glaser, S., Salgia, R., & Amini, A. (2022) · Translational Cancer Research

Explainable Artificial Intelligence (XAI)Artificial Intelligence in Healthcare and Education

Cited by 86

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer

Mohanty, A., Nam, A., Srivastava, S., Jones, J., Lomenick, B., Singhal, S. S., Guo, L., Cho, H., Li, A., Behal, A., et al. (2023) · Science Advances

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 79

Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer

Villaflor, V., Won, B., Nagy, R., Banks, K., Lanman, R. B., Talasaz, A., & Salgia, R. (2016) · Oncotarget

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 75

Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach

Chen, B. T., Chen, Z., Ye, N., Mambetsariev, I., Fricke, J., Daniel, E., Wang, G., Wong, C. W., Rockne, R. C., Colen, R. R., et al. (2020) · Frontiers in Oncology

Radiomics and Machine Learning in Medical ImagingLung Cancer Diagnosis and Treatment

Cited by 63

Biomarkers in Lung Cancer: From Early Detection to Novel Therapeutics and Decision Making

Scott, A., & Salgia, R. (2008) · Biomarkers in Medicine

Lung Cancer Research StudiesLung Cancer Treatments and Mutations

Cited by 59

Precision oncology provides opportunities for targeting KRAS-inhibitor resistance

Sattler, M., Mohanty, A., Kulkarni, P., & Salgia, R. (2023) · Trends in Cancer

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 54

Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention

Reb, A., Ruel, N., Fakih, M., Lai, L., Salgia, R., Ferrell, B., Sampath, S., Kim, J. Y., Raz, D. J., & Sun, V. (2017) · European Journal of Oncology Nursing

Cancer survivorship and careChildhood Cancer Survivors' Quality of Life

Cited by 45

PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma

Kubic, J. D., Lui, J. W., Little, E. C., Ludvik, A. E., Konda, S., Salgia, R., Aplin, A. E., & Lang, D. (2015) · Journal of Biological Chemistry

Chemokine receptors and signalingMelanoma and MAPK Pathways

Cited by 25

Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Zhao, D., Li, H., Mambetsariev, I., Mirzapoiazova, T., Chen, C., Fricke, J., Kulkarni, P., Villaflor, V., Arvanitis, L., Hamilton, S., et al. (2022) · Cancers

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 24

RLIP: An existential requirement for breast carcinogenesis

Singhal, S. S., Salgia, R., Singhal, S., Horne, D., & Awasthi, S. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Drug Transport and Resistance MechanismsCell death mechanisms and regulation

Cited by 10